WALTHAM, Mass.— Biostate AI, a leader in artificial intelligence-powered RNA sequencing, has announced a strategic partnership with the Accelerated Cure Project (ACP), a nonprofit organization focused on advancing research and improving outcomes for individuals living with multiple sclerosis (MS). The collaboration aims to develop next-generation AI models that can predict disease progression and treatment response in MS patients using ACP’s extensive biorepository of biological samples and clinical data.
Under the agreement, Biostate AI will use its proprietary barcode-integrated reverse transcription (BIRT) technology to sequence patient samples from the ACP Repository—one of the largest and most comprehensive MS-related biorepositories in the world. These high-resolution RNA expression profiles will be used to train advanced transformer-based AI models that provide personalized, data-driven insights for MS treatment.
“Biostate’s RNA sequencing and AI technologies offer a unique opportunity to transform our understanding of MS progression and treatment response,” said Sara Loud, CEO of the Accelerated Cure Project. “We are thrilled to collaborate with Biostate AI to unlock the full potential of our biorepository and accelerate innovations that lead to better outcomes for people with MS.”
The ACP Repository contains thousands of blood samples from MS patients and healthy controls, including longitudinal samples linked to detailed clinical and demographic information. This depth of data will enable the development of AI systems that identify molecular patterns tied to disease onset, flare-ups, remission, and treatment effectiveness.
“At ACP, we’ve spent years building a resource designed to fuel breakthroughs in MS research,” said Dr. Stephanie Buxhoeveden, Chief Scientific Officer at ACP. “By partnering with Biostate AI, we’re turning data into actionable insights that could revolutionize patient care.”
Biostate AI will sequence the entire ACP Repository and develop a range of AI models tailored to various clinical and research needs. These models are expected to enhance physicians’ ability to predict disease trajectories and tailor treatments for individuals across the MS spectrum.
“Current MS management often relies on trial and error because predictive tools are limited,” said David Zhang, co-founder and CEO of Biostate AI. “By combining high-throughput RNA sequencing with cutting-edge AI, we aim to provide clinicians with precise guidance to ensure patients receive the most effective therapy at the right time.”
The partnership marks Biostate AI’s expansion into neuroimmunology and underscores its goal of creating scalable, disease-specific AI platforms that support personalized medicine.
“MS is a complex and variable disease, making it a perfect candidate for our adaptable, patient-specific models,” said Ashwin Gopinath, co-founder and CTO of Biostate AI. “We’re excited to collaborate with ACP to build tools that can make a real impact in the clinic.”
The initiative reinforces ACP’s mission to drive progress through collaboration, data sharing, and scientific innovation, while enabling Biostate AI to extend its transformative technology into a therapeutic area with significant unmet need.
